309 related articles for article (PubMed ID: 27593971)
1. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors.
Paldor I; Pearce FC; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971
[TBL] [Abstract][Full Text] [Related]
2. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
3. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Paldor I; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
[TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
5. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
[TBL] [Abstract][Full Text] [Related]
7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
8. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.
Schulze Heuling E; Knab F; Radke J; Eskilsson E; Martinez-Ledesma E; Koch A; Czabanka M; Dieterich C; Verhaak RG; Harms C; Euskirchen P
Mol Cancer Res; 2017 May; 15(5):532-540. PubMed ID: 28148826
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
12. [Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Rösche J; Piek J; Hildebrandt G; Grossmann A; Kirschstein T; Benecke R
Fortschr Neurol Psychiatr; 2015 May; 83(5):286-9. PubMed ID: 26018396
[TBL] [Abstract][Full Text] [Related]
13. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
Armocida D; Frati A; Salvati M; Santoro A; Pesce A
Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
Appin CL; Gao J; Chisolm C; Torian M; Alexis D; Vincentelli C; Schniederjan MJ; Hadjipanayis C; Olson JJ; Hunter S; Hao C; Brat DJ
Brain Pathol; 2013 Jul; 23(4):454-61. PubMed ID: 23289977
[TBL] [Abstract][Full Text] [Related]
15. Tumor location and patient age predict biological signatures of high-grade gliomas.
Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D
Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492
[TBL] [Abstract][Full Text] [Related]
16. Lipidized glioblastoma: pathological and molecular characteristics.
Singh AD; Iftinca M; Easaw JC
Neuropathology; 2013 Feb; 33(1):87-92. PubMed ID: 22640269
[TBL] [Abstract][Full Text] [Related]
17. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
De Carlo E; Gerratana L; De Maglio G; Buoro V; Cortiula F; Gurrieri L; Isola M; Fasola G; Puglisi F; Pizzolitto S; Rizzato S
J Neurooncol; 2018 Dec; 140(3):559-568. PubMed ID: 30132165
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.
Dahlrot RH; Dowsett J; Fosmark S; Malmström A; Henriksson R; Boldt H; de Stricker K; Sørensen MD; Poulsen HS; Lysiak M; Söderkvist P; Rosell J; Hansen S; Kristensen BW
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):172-184. PubMed ID: 28574607
[TBL] [Abstract][Full Text] [Related]
19. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
20. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]